{'fraction_non_alphanumeric': 0.02702702702702703, 'fraction_numerical': 0.006142506142506142, 'mean_word_length': 5.417322834645669, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Design and Synthesis of a Photoisomerizable Second Generation Kinase Inhibitor

BCR/ABL is a chimeric oncogene made up of breakpoint cluster region protein (BCR) from chromosome 22 and Abelson murine leukemia (ABL) from chromosome 9. This genetic recombination results in a shortened chromosome 22, which is also known as the Philadelphia Chromosome. The BCR/ABL fusion protein produced as a result of this translocation mutation causes the resulting tyrosine kinase enzyme to become constitutively active. Given the critical regulatory role of ABL in cell division, its constitutive activation results in uncontrollable cell division, which in this case, most often leads to chronic myeloid leukemia (CML). BCR/ABL has also been associated with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).